Teva- Pharmaceutical Industries Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.5%projected annual EPS growth
Analyst Coverage
10analysts covering
Monitoring Framework
Key Performance Indicators
AUSTEDO Global Revenues Quarterly2.3BTarget: $2.4 billion to $2.55 billion (2026 Guidance); $2.5 billion peak by 2027
Non-GAAP Operating Income Margin Quarterly24.3%Target: 30% by 2027
Net Savings from Teva Transformation Programs Annually70MTarget: ~$700 million of net savings by 2027 (with two-thirds realized by 2026)
Free Cash Flow Annually2.4BTarget: $2.0 - $2.4 billion (2026 Guidance); >$2.7 billion by 2027; >$3.5 billion by 2030
Net Leverage Ratio (Net Debt / EBITDA) Quarterly2.5xTarget: 2.0x net leverage by 2027
Watch Items
- Regulatory approval and launch of olanzapine long-acting injectable (LAI)Trigger: FDA decision expected in 2026Action: Monitor FDA regulatory milestones and initial commercial launch metrics to validate neuroscience franchise expansion.
- Divestiture of the Active Pharmaceutical Ingredients (API) business unit (TAPI)Trigger: Execution of planned divestiture announced under Pivot to Growth strategyAction: Track transaction progress, final valuation, and cash proceeds allocation toward debt reduction.
- Clinical trial data readouts for duvakitug (anti-TL1A)Trigger: Phase 2/3 data readouts in ulcerative colitis and Crohn's diseaseAction: Evaluate efficacy and safety profiles against competitors to assess blockbuster immunology potential.
Research as of 2 Sep 2026